Table 2.
Comparison of pathologic upstaging in potential active surveillance patients
| Variable | Group 1A (n = 721) No upstaging |
Group 1B (n = 29) Upstaging |
P value/X2 |
|---|---|---|---|
| Mean age | 59 ± 6.9 | 60.6 ± 7.0 | 0.208 |
| Mean BMI | 26.9 ± 3.8 | 28.7 ± 4.7 | 0.018 |
| Mean preop PSA | 4.6 ± 1.9 | 5.0 ± 1.9 | 0.261 |
| Total Bx cores | 0.582 | ||
| <18 | 87.8 | 84.4 | |
| ≥18 | 12.2 | 11.1 | |
| Total positive cores | 0.051 | ||
| 1 | 68.9 | 51.7 | |
| 2 | 31.1 | 48.3 | |
| Max % of cancer in biopsy | 0.502 | ||
| ≤5 | 51.2 | 44.8 | |
| >5 | 48.8 | 55.2 | |
| Clinical stage | 0.331 | ||
| T1 | 96.5 | 93.1 | |
| T2a | 3.5 | 6.9 | |
| HGPIN on Bx | 0.695 | ||
| No | 88.6 | 86.2 | |
| Yes | 11.4 | 13.8 | |
| Prostate volume | 54.2 ± 23.3 | 46.7 ± 16.7 | 0.025 |
| Gleason pathology | <0.0001 | ||
| ≤6 | 61.9 | 20.7 | |
| 7 | 37.8 | 75.9 | |
| 8, 9, 10 | 0.3 | 3.4 | |
| pTNM | <0.0001 | ||
| T1–2 | 100 | 0 | |
| T3–4 | 0 | 100 | |
| Positive SM rate | 3.7 | 27.6 | <0.0001 |